About US
Contact us
-
Amid insulin market scrutiny, Novo faces class action alleging 'collusive price fixing'While all of biopharma felt the sting of tough talk from President-elect Donald Trump on Wednesday, Novo Nordisk faced some fresh concerns of its own. A New York law firm said it filed aclass actionsu2017/2/10
-
Regeneron CEO: Amgen's disruptive Praluent-blocking patent move hurts patientsSAN FRANCISCO—Last week, a U.S. District Courtblocked salesof Sanofi and Regeneron’s PCSK9 med, Praluent, as part of an ongoing patent war with Repatha-maker Amgen. And Monday at the J.P. Morgan Healt2017/2/9
-
J&J and Actelion reportedly take complicated deal to Swiss regulator for rulingThere is evidence that Actelion and Johnson & Johnson are edging closerto a deal to give the U.S. drugmaker control of the Swiss biotech, sort of. Citing a report in the Swiss newspaper Tages-Anz2017/2/9
-
Sanofi and Regeneron ordered to halt Praluent sales, but companies to appeal judge's decisionA U.S. federal judge handed Sanofi and partner Regeneron a stunning loss with a ban on sales of their cholesterol-lowering drug Praluent in the U.S. after a jury said it infringed Amgen’s patent for r2017/2/8
-
Sanofi, Regeneron one step closer to owing PCSK9 royalties as judge upholds Amgen patent rulingAmgen has been in a tight race with Sanofi and Regeneron to win market acceptance for a new class of drugs that fight ultra-high cholesterol by inhibiting an enzyme called PCSK9—a fight that includes2017/2/8
-
Trump to Pharma CEOs: 75% to 80% of FDA Regulations Will be EliminatedTrump to Pharma CEOs: 75% to 80% of FDA Regulations Will be Eliminated 唐纳德?特朗普总统周二告诉制药公司的CEO们,他的管理团队会以前所未有的方式裁撤制药行业的法规,这也预示着美国FDA(食品药品管理局)将要发生的事情。 In a sign of what’s to come for the US Food2017/2/7
-
Should the U.S. try M&A to save on hep C? Gilead would be a good buy, experts sayHere’s a radical solution for hepatitis C treatment in the U.S.: The government could play private-equity investor and buy the leading drugmaker in the field, Gilead Sciences. Price: $156 billion. Pay2017/2/7
-
McKesson paying record $150M to settle with feds over opioid salesSome years back, McKesson got fined $13.25 million for not reporting suspicious sales of controlled drugs from its distribution centers. The feds now say the drug distributor didn’t learn its lesson a2017/2/6
-
Bad news for biosim makers: FDA sets 'high bar' in interchangeability guidanceThe FDA rolled out much-awaited biosimilar interchangeability draft guidelines Tuesday, tipping its hand to developers looking to challenge sales of the world’s top biologics. The gist? Winning the de2017/2/6
-
Drugmakers 'hijacked' the FDA's orphan system to score premium pricing on mass-market meds: reportThere’s no denying that financial incentives for orphan drug development spawned meds that have saved hundreds of thousands of lives. But they’ve also helped mass-market drugmakers rack up millions in2017/2/4